{"id":"fluad-alone","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":"10-20","effect":"Myalgia"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"1-5","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluad contains inactivated influenza virus antigens combined with the MF59 oil-in-water emulsion adjuvant, which amplifies the body's adaptive immune response to the vaccine antigens. The adjuvant stimulates innate immunity and increases antibody production and cellular immune responses compared to non-adjuvanted influenza vaccines. This formulation is particularly designed to improve immunogenicity in older adults and other populations with potentially weaker immune responses.","oneSentence":"Fluad is an inactivated influenza vaccine adjuvanted with MF59 that enhances immune response to seasonal influenza strains.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:34.666Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults aged 65 years and older"},{"name":"Seasonal influenza prevention in adults at high risk of complications"}]},"trialDetails":[{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT07386509","phase":"EARLY_PHASE1","title":"WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues.","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2020-03-17","conditions":"Healthy","enrollment":2},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT04101838","phase":"PHASE4","title":"B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-04-01","conditions":"Influenza","enrollment":50},{"nctId":"NCT06054269","phase":"PHASE3","title":"Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-11-04","conditions":"Influenza","enrollment":192},{"nctId":"NCT05568797","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":"Respiratory Syncytial Virus Infections","enrollment":1045},{"nctId":"NCT03694808","phase":"PHASE4","title":"FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care","status":"COMPLETED","sponsor":"David H. Canaday","startDate":"2018-09-23","conditions":"Flu","enrollment":478},{"nctId":"NCT06029933","phase":"","title":"Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years","status":"RECRUITING","sponsor":"Kaiser Permanente","startDate":"2023-08-17","conditions":"Influenza, Community-acquired Pneumonia, Cardiovascular Events","enrollment":960000},{"nctId":"NCT04622592","phase":"PHASE1, PHASE2","title":"Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Medicago","startDate":"2020-11-02","conditions":"Influenza","enrollment":209},{"nctId":"NCT03603509","phase":"PHASE4","title":"Gene Signatures of Influenza Vaccine Responses in Older Adults","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-08-27","conditions":"Influenza","enrollment":241},{"nctId":"NCT02523287","phase":"PHASE4","title":"Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2014-10-02","conditions":"Safety Markers of Adjuvanted Influenza Vaccine","enrollment":240},{"nctId":"NCT04077424","phase":"PHASE4","title":"Senescent Immunity in Elders and Vaccine Responses (SILVER)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-10-21","conditions":"Flu Vaccine","enrollment":10},{"nctId":"NCT03698279","phase":"PHASE2","title":"Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-09","conditions":"Influenza","enrollment":665},{"nctId":"NCT00841763","phase":"PHASE3","title":"Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Pandemic Influenza Disease","enrollment":3647},{"nctId":"NCT03183908","phase":"PHASE4","title":"FLUAD® vs. Fluzone® High-Dose Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-08-28","conditions":"Pain, Quality of Life, Injection Site Reaction","enrollment":757},{"nctId":"NCT00478816","phase":"PHASE2","title":"Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-05","conditions":"Prophylaxis of Avian Influenza Vaccine","enrollment":58},{"nctId":"NCT00734734","phase":"PHASE2","title":"Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-06","conditions":"Interpandemic Influenza","enrollment":64},{"nctId":"NCT02215863","phase":"PHASE4","title":"Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2014-09","conditions":"Influenza, Streptococcus Pneumoniae","enrollment":1195},{"nctId":"NCT01771367","phase":"NA","title":"Training Study to Characterize Biomarkers to Flu Vaccines","status":"COMPLETED","sponsor":"University of Surrey","startDate":"2013-01","conditions":"Healthy","enrollment":49},{"nctId":"NCT02225327","phase":"PHASE4","title":"MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2013-10","conditions":"Influenza, Human, Pneumococcal Infections","enrollment":224},{"nctId":"NCT01651104","phase":"PHASE2","title":"Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2012-07","conditions":"Human Influenza","enrollment":63},{"nctId":"NCT01879540","phase":"PHASE2","title":"Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-07","conditions":"Human Influenza","enrollment":63},{"nctId":"NCT00522236","phase":"PHASE2","title":"Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-06","conditions":"Influenza","enrollment":56},{"nctId":"NCT00984945","phase":"PHASE1","title":"Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2009-09","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Fluad alone","genericName":"Fluad alone","companyName":"Korea University Guro Hospital","companyId":"korea-university-guro-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"Fluad is an inactivated influenza vaccine adjuvanted with MF59 that enhances immune response to seasonal influenza strains. Used for Seasonal influenza prevention in adults aged 65 years and older, Seasonal influenza prevention in adults at high risk of complications.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}